Canid, a New York-based end-to-end platform for vaccine automation and management, closed $1.5 million in funding.
The round was led by SeedtoB Capital, with participation from FJ Labs, Alumni Ventures, I2BF, and MKT1.
SeedtoB Capital invests in early-stage businesses, driving the adoption of innovative technology within the healthcare ecosystem. Based in Atlanta, GA, SeedtoB Capital is focused on helping entrepreneurs navigate the complexities of healthcare and chart the most efficient path toward Series B – and ultimately, company success.
Canid Use of Funds
The funding will be used to expand Canid's geographic footprint to 10 new states across the United States. Additionally, the funds will support the development of new tools aimed at managing vaccine patient populations more effectively.
Canid is an end-to-end vaccine workflow automation and management solution, allowing practices to more effectively manage the purchasing, delivery, and record management of vaccines. By eliminating the administrative complexity of vaccine delivery, Canid empowers clinicians to deliver higher-quality care and ultimately drive improvements in public health.
Funding Month: September 2023
Lead Investors: SeedtoB Capital
Additional Investors: FJ Labs, Alumni Ventures, I2BF and MKT1
Company Website: https://www.canid.io/
Software Category: Vaccine Automation and Management